ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SHP Shire

4,690.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shire LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4,690.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Shire Share Discussion Threads

Showing 2051 to 2074 of 5350 messages
Chat Pages: Latest  94  93  92  91  90  89  88  87  86  85  84  83  Older
DateSubjectAuthorDiscuss
04/8/2017
08:50
4th aug RBC outperform tp $213 cut from $214
4th aug HSBC hold tp 4480p up from 4450p

philanderer
04/8/2017
08:48
For anyone interested a few recent decent articles on Seeking Alpha
looking at SHP in detail.

essentialinvestor
04/8/2017
08:46
Morning Phil, intend to add in small amounts.
essentialinvestor
04/8/2017
08:45
Morning EI , luck with those.


So , this not helping the shareprice now.. :-S


FT.

Analysts at Deutsche Bank said the review of the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v M&A]”.

philanderer
04/8/2017
08:40
It's fascinating looking at the recent GSK statement where they are moving away
from rare diseases, the very area Shire focus on.

essentialinvestor
04/8/2017
08:36
My entry level approaching 4000
a2584728
04/8/2017
08:31
Bought a few.
essentialinvestor
04/8/2017
08:28
Think it's still the Roche potential treatment weighing on sentiment.
essentialinvestor
04/8/2017
08:09
Dollar related, weak dollar is not good for Pharma
bigboots
04/8/2017
08:00
It's a weird performance for sure. Can't see any downgrades


4th aug JP Morgan Caz overweight -
4th aug Deutsche buy tp 6000p
4th aug Credit Suisse outperform tp 5350p

reiterations

philanderer
04/8/2017
07:17
Sterling strength? Brexit obliterated sterling in the short and medium term. Plus biotechs are going greats guns - look at IBB the biotech index.

In my view SHP has many tailwinds and that's why I got involved, but tbh sitting on a small loss at present. Gutted.

ruethewhirl
03/8/2017
23:19
The ADRs are near 40% off their high of two years ago.

Healthcare out of favour,summer lull,sterling strength,technical weakness...you can seek any number of explanations but you'll be chasing your tail to explain this continued underperformance.I see that Inmarsat got given the roller coaster ride today too.I think I'll blame algorithmic trading.Since I have no intention of selling Shire though,I don't need to struggle too hard to make sense of it all.

steeplejack
03/8/2017
22:21
Market report:

Elsewhere in healthcare, pharmaceuticals firm Shire has launched a review which could see it split in half.

The company's neurosciences division is responsible for around a fifth of its sales and is a big earner in America, where its ADHD drugs are hugely popular.
Chief executive Flemming Ornskov described it as an 'incredibly strong business that could stand alone'.

New York and London are both thought to be contenders to host the new business.
A separation would leave Shire free to put all its energy into its rare diseases arm.

This is the key money-spinner and has made valuable breakthroughs in immunology, haematology, internal medicine, eye ailments, oncology and anti-virals.
'We are at an exciting inflection point,' Ornskov said. Shares slipped 2 per cent, or 82p, to 4118p.





Read more:

philanderer
03/8/2017
20:31
When I flicked through the results I thought oh great finally we will rally.
ruethewhirl
03/8/2017
20:29
Takeover rumours are exactly that. Rumours.

I held onto Aveva for an entire year because of rumours AND an approach, which then fell through.

ruethewhirl
03/8/2017
20:02
Closed down 3.4% in US
greenrichard
03/8/2017
17:54
Some platforms such as Interactive Investor showing a closing share price of 4205p.

Lots of buys showing up to 1711

justiceforthemany
03/8/2017
17:34
Amazing that the share price fell today after positive results and a rise in EPS to $15/share ADS or $5/share for us.

This is giving a P/E of only 10.7

Pfizer, Eli Lilly, Roche, Novartis all have market caps >$200Bn so could easily swallow Shire and all trade with P/E's around 30.

justiceforthemany
03/8/2017
17:30
5300p/share? RUMOURED BID FOR SHIRE
Evening Standard

The City rumour mill was in full flow today as deal-hungry traders suggested drug-maker Shire was back in play.

Gossips said some of the biggest drugs firms in Europe and the US have hired advisers ahead of a possible tilt at the Dublin-based company.

They added that Shire, fearing lowball bids, had hired defence advisers.

Earlier this month, the FTSE 100 company’s chief executive Flemming Ornskov hinted that investors were valuing Shire too low after a 10% fall from the share price this year.

He pointed to the healthy pipeline of drugs, including for ADHD and haemophilia, which came as part of the £22 billion acquisition of Baxalta.

Shire accepted a £32 billion cash and shares bid in 2014 from US rival AbbVie worth around 5300p per share before a clampdown on tax inversion deals scuppered the takeover.

The shares now languish at 4284.5p, up another 63.31p, or 1.5%, today after gaining ground yesterday, valuing the firm at £39 billion. Shire declined to comment on the speculation.

justiceforthemany
03/8/2017
16:18
'Shire may spin off ADHD drugs business'

The pharma company upgraded guidance after strong first half

Analysts at Jefferies said a spin-off of the ADHD business had been mooted many times, but it now seemed reasonable given Baxalta had catapulted the transition into rare diseases, and Mydayis would extend the ADHD portfolio’s lifecycle beyond Vyvanse’s 2023-24E expiries.

philanderer
03/8/2017
14:09
I think it's a mix of:

healthcare out of favour right now so profit taking here not being full offset by new buyers

strategic review creates uncertainty

I am surprised about the dip below open because they have good results here and they are upping their forecast

A couple of analysts on the call obviously hostile

romeike
03/8/2017
14:05
That jump was short lived :-O

Conference call not gone down too well ??


'Shire ups earnings guidance as second quarter sales surge'

philanderer
02/8/2017
16:53
Q2 results at midday rtomorrow
philanderer
28/7/2017
16:42
SHP and BRBY the only ones up for me this week out of twenty .

Cr@p five days.

philanderer
Chat Pages: Latest  94  93  92  91  90  89  88  87  86  85  84  83  Older

Your Recent History

Delayed Upgrade Clock